0001628280-21-024931.txt : 20211213 0001628280-21-024931.hdr.sgml : 20211213 20211213160547 ACCESSION NUMBER: 0001628280-21-024931 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211213 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211213 DATE AS OF CHANGE: 20211213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avanos Medical, Inc. CENTRAL INDEX KEY: 0001606498 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 464987888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36440 FILM NUMBER: 211488140 BUSINESS ADDRESS: STREET 1: 5405 WINDWARD PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 678-425-9273 MAIL ADDRESS: STREET 1: 5405 WINDWARD PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 FORMER COMPANY: FORMER CONFORMED NAME: Halyard Health, Inc. DATE OF NAME CHANGE: 20140424 8-K 1 avns-20211213.htm FORM 8-K avns-20211213
0001606498falseDecember 13, 202100016064982021-12-132021-12-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: December 13, 2021
(Date of earliest event reported)
avns-20211213_g1.jpg
AVANOS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Commission file number 001-36440
Delaware46-4987888
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
5405 Windward Parkway
Suite 100 South
Alpharetta,Georgia30004
(Address of principal executive offices)(Zip code)
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock - $0.01 Par ValueAVNSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 1.01    Entry into a Material Definitive Agreement
On December 13, 2021, Avanos Medical Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among its wholly owned subsidiary Avent, Inc. (“Avent”), Orthogen Merger Sub, Inc., a newly-formed wholly owned subsidiary of Avent (“Merger Sub”), OrthogenRx, Inc., a Pennsylvania corporation (“OrthogenRx”), and Shareholder Representative Services LLC, as representative of OrthogenRx’s equityholders. Pursuant to the Merger Agreement, OrthogenRx will merge with and into Merger Sub, with OrthogenRx surviving the merger as a wholly owned subsidiary of Avent (the “Merger”). The total purchase price payable by the Company in the Merger is $130.0 million in cash at closing, on a cash-free, debt-free basis and subject to adjustments based on the net working capital of OrthogenRx at the closing, plus up to an additional $30.0 million in contingent cash consideration based on OrthogenRx’s growth in net sales during 2022 and 2023. The Company expects the Merger to close in the first quarter of 2022.
The closing of the Merger is subject to the satisfaction or waiver of certain customary conditions to closing, including, among others, (i) expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii) the absence of any law or order issued by a court or other governmental authority prohibiting or enjoining the Merger or making illegal the Merger, and (iii) approval of the Merger Agreement and the Merger by OrthogenRx’s shareholders. Each party’s obligation to consummate the Merger is also conditioned upon the accuracy of the other party’s representations and warranties (generally subject, other than for certain representations and warranties, to a material adverse effect standard) and the other party’s having performed in all material respects its obligations under the Merger Agreement. Avent’s and Merger Sub’s obligation to consummate the Merger is further subject to (i) the absence of a change, event or occurrence that has had or would reasonably be expected to have a material adverse effect on OrthogenRx and (ii) the exercise of dissenters’ rights by holders of no more than 10% of OrthogenRx’s outstanding shares.
The Merger Agreement contains customary representations, warranties and covenants from both OrthogenRx and Avent and Merger Sub, including covenants from OrthogenRx to conduct its business in the ordinary course and not to take certain actions between the signing of the Merger Agreement and the closing of the Merger. The Company has obtained representation and warranty insurance, which provides coverage for losses related to breaches of the representations and warranties of OrthogenRx contained in the Merger Agreement, subject to deductibles, policy limits and certain other terms and conditions. Subject to certain exceptions and limitations, the OrthogenRx equityholders and Avent and the Company have agreed to indemnify each other for breaches of covenants and other specified matters contained in the Merger Agreement. A total of $3.0 million of the purchase price otherwise payable in the Merger at the closing will be held in an escrow account for a period of up to three years to satisfy the OrthogenRx equityholders’ specified indemnification obligations.
The Merger Agreement also contains certain customary termination rights for each of Avent and OrthogenRx. The Merger Agreement may be terminated by mutual consent of Avent and OrthogenRx or, subject to certain conditions, by either Avent or OrthogenRx if the closing of the Merger has not occurred prior to June 1, 2022 or if a law makes illegal or a governmental authority has issued a final, non-appealable order prohibiting, enjoining or restraining the Merger. The Merger Agreement may also be terminated by either Avent or OrthogenRx if, subject to certain conditions, the other party is in breach of its representations or warranties or covenants in the Merger Agreement and such breach would prevent the satisfaction of its closing conditions and is incapable of or has not been cured within 15 days. In addition, Avent may terminate the Merger Agreement if, within 24 hours following the parties’ execution and delivery of the Merger Agreement, OrthogenRx has not delivered evidence of approval of the Merger Agreement by the OrthogenRx shareholders.
The Merger Agreement contains various representations and warranties made by the parties solely for the benefit of the other parties to the Merger Agreement. In addition, such representations and warranties (a) have been made only for purposes of the Merger Agreement, (b) have been qualified by confidential disclosures made to the other parties in connection with the Merger Agreement, (c) are subject to materiality qualifications contained in the Merger Agreement that may differ from what may be viewed as material by investors, (d) were made only as of the date of the Merger Agreement or such other date as is specified in the Merger Agreement, and (e) have been included in the Merger Agreement for the purpose of allocating risk between the contracting parties rather than establishing matters as facts. Investors should not rely on the representations or warranties or any descriptions thereof as characterizations of the actual state of facts or condition of OrthogenRx or the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information regarding the Company that is or will be contained in, or incorporated by reference into, the Forms 10-K, Form 10-Q and other documents that the Company files or has filed with the SEC.
The foregoing description of the Merger Agreement and the Merger does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, which will be filed with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.


This Current Report contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the timing of the expected closing of the Merger. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Actual results could differ materially from those expected as a result of a variety of factors, including legislative and regulatory actions or any failure to meet, or delay in meeting, the closing conditions in the Merger Agreement. The Company assumes no obligation to update any forward-looking information contained in this Current Report.
Item 7.01    Regulation FD Disclosure
On December 13, 2021, the Company issued a press release announcing that it had entered into the Merger Agreement. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference.
The information, including exhibits attached hereto, in Item 7.01 of this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.
Item 9.01    Financial Statements and Exhibits
(d)Exhibits.
    The following exhibits are filed with this Current Report on Form 8-K:
Exhibit No.Description
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    
AVANOS MEDICAL, INC.
Date: December 13, 2021By:/s/ Mojirade James
Mojirade James
Senior Vice President and General Counsel


 EX-99.1 2 avnsform8k_12132021xex991.htm EXHIBIT 99.1 Document
Exhibit 99.1
avanoslogo.jpg
Investor Contact: Michael Greiner
Avanos Medical, Inc.
470-562-2692
Investor.Relations@Avanos.com
Media Contact: Katrine Kubis
Avanos Medical, Inc.
470-448-5561
CorporateCommunications@Avanos.com

Avanos Medical, Inc. Announces Agreement to Acquire OrthogenRX, Inc.
Intra-articular injections products enhance pain portfolio with additional treatment options
ALPHARETTA, Ga., Dec. 13, 2021 / PRNewswire / -- Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire OrthogenRx, Inc., an emerging leader in viscosupplementation therapies for the treatment of knee osteoarthritis (OA) pain, for a total consideration of $160 million. The purchase price consists of $130 million in cash at closing plus an additional $30 million in contingent cash consideration, payable upon the achievement of growth milestones related to the company’s commercial hyaluronic acid (HA) therapy products, GenVisc® 850 and TriVisc®.
The treatment of OA knee pain with HA therapy represents a commercial opportunity of $1 billion in the U.S. The addition of GenVisc 850 and TriVisc – both approved by the U.S. Food and Drug Administration and indicated for the treatment of OA knee pain in patients who have failed to respond adequately to conservative, non-pharmacologic therapy and simple analgesics – will complement Avanos’ pain portfolio of COOLIEF* Cooled Radiofrequency treatment for knee OA.
HA injections are a nonsurgical option that clinicians use to treat millions of patients impacted by pain and sustained discomfort due to knee OA. These injections can play a key role in the continuum of care for patients, often providing interim pain relief before transitioning to the next level of treatment options, including COOLIEF*.
“The acquisition of OrthogenRx enhances our chronic pain portfolio by providing continuum of care treatment options for patients living with knee OA,” said Avanos Chief Executive Officer Joe Woody. “This business is a clear strategic fit for Avanos, and one that will further strengthen our relationships with healthcare providers as we seek to become their preferred partner in treating musculoskeletal pain.”
Michael Daley, PhD, and J. David Owens, OrthogenRx, Inc. Co-Presidents and Co-Chief Executive Officers, offered the following comment: “We are extremely proud of our team’s accomplishments, and finding a partner such as Avanos with a similar culture, dedication and focus on patient care is

Exhibit 99.1
exciting and important for OrthogenRx. This is truly a synergistic integration that creates value for all stakeholders as well as future opportunities for our existing products and pipeline.”
The transaction is expected to close in Q1 2022, subject to customary closing conditions including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Avanos will finance the acquisition through a combination of funds from its existing credit facility and available cash. The company estimates that the new business will contribute approximately $65 million in 2022 revenue and will be immediately accretive to gross and operating margins.
Alston & Bird LLP is serving as legal counsel to Avanos. Canaccord Genuity LLC is serving as financial advisor to OrthogenRx and Blank Rome LLP is serving as its legal counsel.
About Avanos Medical: Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.
About OrthogenRx:
OrthogenRx, Inc. is a medical device company focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA). OA is the most common cause of knee pain, causing sufferers significant pain and disability. OrthogenRx aspires to provide every patient with the products they need and assist in getting them back to a life without OA knee pain. Learn more at www.orthogenrx.com, www.genvisc850.com and www.trivisc.com.
Media Contact
OrthogenRx Inc.
c/o CG Life – Public Relations
Alison Guzzio, 484-459-3243
PR-Communications@orthogenrx.com
1515 Market St #1200
Philadelphia, PA 19102
GenVisc 850 and TriVisc are registered trademarks of OrthogenRx, Inc.
SOURCE Avanos Medical, Inc.

Note Regarding Forward-Looking Statements
This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking

Exhibit 99.1
statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may," "believe”, "will," “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue” and similar expressions, among others. The "forward-looking statements" include, without limitation, statements regarding the acquisition’s impact on the Company’s chronic pain portfolio including Company revenues and gross and operating margin, the timing of the closing, and the Company’s source of funds for the acquisition. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Actual results could differ materially from those expected as a result of a variety of factors, including weakening of economic conditions that could adversely affect the level of demand for products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for products; shortage in drugs or other disruptions in our supply chain; changes in foreign exchange markets; legislative and regulatory actions; changes in reimbursement levels from third-party payors; product liability claims; and changes in the competitive environment. Additional information concerning these and other factors that may impact future results is contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission.

 EX-101.SCH 3 avns-20211213.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avns-20211213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 avns-20211213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 avanoslogo.jpg AVANOS LOGO begin 644 avanoslogo.jpg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end GRAPHIC 7 avns-20211213_g1.jpg AVANOS LOGO begin 644 avns-20211213_g1.jpg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end XML 8 avns-20211213_htm.xml IDEA: XBRL DOCUMENT 0001606498 2021-12-13 2021-12-13 0001606498 false 2021-12-13 8-K 2021-12-13 AVANOS MEDICAL, INC. 001-36440 DE 46-4987888 5405 Windward Parkway Suite 100 South Alpharetta, GA 30004 844 428-2667 false false false false Common Stock - $0.01 Par Value AVNS NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page Cover Page
Dec. 13, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 13, 2021
Entity File Number 001-36440
Entity Registrant Name AVANOS MEDICAL, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-4987888
Entity Address, Address Line One 5405 Windward Parkway
Entity Address, Address Line Two Suite 100 South
Entity Address, City or Town Alpharetta,
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30004
City Area Code 844
Local Phone Number 428-2667
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock - $0.01 Par Value
Trading Symbol AVNS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001606498
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Cover Page Sheet http://www.avanos.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports avns-20211213.htm avns-20211213.xsd avns-20211213_lab.xml avns-20211213_pre.xml avnsform8k_12132021xex991.htm avns-20211213_g1.jpg http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "avns-20211213.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "avns-20211213.htm" ] }, "labelLink": { "local": [ "avns-20211213_lab.xml" ] }, "presentationLink": { "local": [ "avns-20211213_pre.xml" ] }, "schema": { "local": [ "avns-20211213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avns", "nsuri": "http://www.avanos.com/20211213", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "avns-20211213.htm", "contextRef": "i113c24c50f004b17b93568812a7c3877_D20211213-20211213", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Cover Page", "role": "http://www.avanos.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "avns-20211213.htm", "contextRef": "i113c24c50f004b17b93568812a7c3877_D20211213-20211213", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001628280-21-024931-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-024931-xbrl.zip M4$L#!!0 ( +> C5/-ZQFHJAX ,JT 1 879NL^W4W60D;SX"3TXH!#DX-- B:T>D\XHRRZE($T&TEF27H971);Y,[O) M<)J&%[U[Y+Y8!ZIF/H-J.FLGG14#W5 M,'T]D W3HK+A4$UVJ:;(9F!Y&O%=6PO,3=IP--=1#4>'1EW#IYZC!T;@F*;. M=)7HS,1N>SG,#F889Q]KO3P?-K:VQN-Q?:S7D_1B2W5==VN"]]3$38UPDB_< M./'2B-\:QE$8,Z3)5IZ2. N2=$!RH-D6S%21%4U6M;(1N/-R?2N:HNA;>-DC M&2MOGZS@;$8DO M/M98+)^>U(#!C-#M#P.6$PD?E=G_1N'5Q]IN$N<@MG)G.H3V??'M8RUGDWR+ M\WMK^V]_^]N'/,PCMDVNXDS&#E1-U3]LB1\_;(FFO81.MS_0\$K*\FG$/M9H MF TC,FW$2R5'P,*64Q_PC7VZ [:>B+_B?Y,0L^UD)5U7W-\$TE M4!3#4VW/U4W+<52-V+[NV/;WO7(HLS'5I)@,L&L6-IHQC&^Z"]-)27004S;Y M@TUK4DBA::I_FWI[R=6A=GS5U5LCVF]>G>^[_:/^Q?2H[;4'[?VNT>Z<7I]W6I,N/-?^YBB'VOFT>^9;W>OSL#WHZD=[EVIK\/FR MO==4VH.FT;[NA:V.#_V?*NT]'Y^_HON?0F__U&IU6N-6YU0[[Q^,6VHI!M&HHCAF;5L!F;44RW"=#UL+3/V5/-X!R*4(NY\B<&MYI?Q>=K*U0*B2 MJC,R;E4L^1;8>V'T.3GO\C2_J[7J,X6C, ACN?(\SDTD47L0-'TC- MTJ*M\G8_B9*T\7>%_WL? "GD@ S":-KX5R<<@$"WV5@Z3@8D_M=F!DXD>)MI M&(@;L_":-50->N%?QV)J-K2#_F(Y557#R9VV#SK-/>FDL]-IGBQ.X>4/_J2Y M>WI\T#EHGD@[[3VI^=_=_^RT]YO2[E&K=7!R[]SU-Z4 M]NJ[=8 Y,) _,XN<>!$K[_>2%-1&AME$9)BQ1OGA?>DKBY!"Y@^]+UKWDCQ/ M!@U4"P@_\] G4=$)[T]<+C1&=^N*;J+2Y*"=.2T[+O2ISO5I*Z>KUURG[BHW M7U;JZNS:%F\[+6\H"*AS?83G8%)(KH\UL.F+\RYFH@YS*4NBD$HE0X>$TC"^ M:"B2REN9=[/%2?$2!,BZEP!].CIN24_@&HEX[3D]G4GIZ9R??;ML]UN35N=S MCWLI^RWS:/_SY7G_]][1_JD.7H[:[4 _G4OP6KX9]#^?HW,MNO+ZP^C\[*O6 MNFY.6H-/W$N!/HWNX'C0VF\:YQU?:5]_Z[7.FI,CZ*_5:6K?5=\P+%,S9,L* M=-D(7$?V%/1?J6TRUS=LQ85@Q)'_6/5-A [_6J$PU@K%/_\.]O[]&XH\#HH@ MG5XGA"S;H/72 C;UN-GN2,?-+T?'G9=C095[C?[+*,U&),ZE/)%.F(]Y-8@7 MI 2B!G.#OI.20,I[#"^-TC /H>/FQ.]!9,"D'3_'RZJK&R]WUNMA'_UH'/LQ M&R9IWG@*"_ *@^,G-QE'G=9CQ;;2RQ7)]8JX4U"02Y3==6IJ9.9P\A!F:"@_6MEZB(JS' MYE^^QG#,+L(,EY+R-ESYBT$L>.73[RZE%O4 8W6B:K*A$TMV-8W*NFT$AF;Z MON4KM>V=;SOMHQ.IU=P[V-TYW)0.VKOUUP^SS0D!OP5E L$VG^I2 $Y(]'W%C^5]_ M+;6:PO-F:^_@NM4_U8[V+L??3=]5?)/I^6[JJBU!5!OA\EO*[6P<.^%^%_I%FC;KKZH[?J MU"WGYBU"SMW=IN?8O(*RMNX_>*DB!I=Q/"@KU6]0U:Z9KI3II MPPDJU*IRK$AS,GQZRZ@\B7=Y$/M)"B$;+U$ZR2&HVTU&<9Y.=Q.Z&/=CQ1.N M_^5LF"97V,XK#?C%:GA;P[:ZTZ.]3Y?MCC]N[^V8YYU+I=T_A3'T(AC#N'OM MZ^U!=WDU7#_'_OLPC[.O:OMZ1VGM1=%1YZO6[L!\]T]AOK_WV]>^=AXYX\/. MSN)J.'$T5]6M0&:$41D89\G$L'V9J(;EJZ:N4<_"C$%$QB1=K8LH#6VA VM, MR5IK\>MO?=.O=?K5(9.#8OG=YSKVBOW-IU:_"5@>-J.H&NJ[2V;5BRX3JVXZQ6BE55Y[%-A/!U'EN*G;N"1"[$&QRW,0F> MY#V(F_JC-,QH*++C$#6&58Q_]Z=$D&A;2K-;G$TQR;F+Y, ]L!.-5T MF00.DTV;.>"J.+IN*K5MTU!,Z2R,*?@I5/I"TLLQF3Z6O_*F(T^G(]J;CMRE M(]>K=>M 84=73-FS'54V;-60B6(;LD$<%FA:H!!#JVV?C$*PS,!9Z209Y;V7 MHATOSM*^,.78A8]':2<9OT6X=ZJ&LJ(:IFI0V[:)[!C@GAL>(3)QO$#6&&6: MX0"7F%_;WHF&/0AP\YQL_H1:O,EM56YY('"4?DF3JY!OZ7K+W_R\=+>6@#_0 M \?5J>SHS)<-BU#9]1PJJXINF[H"P:C*:MO[+$DO0G)OR7Y#Y-LE^TL"HAN= MAT.1EWP3VSO%]NNBV#JJQ0SJNK)/<(6/Z);LJ;HI!YH>,(?HOND#*.L@+<9+ M\5+OX0>BS[.9$S(O#@GO.&[03 M)D'9@U-,]U[2U%]0\<*\/N>??WX]FV3*BBR8:FZ;+C*)[LN2IU;.H; MQ#-JVXZQ G;O?F79R6$"JOH%)>,5+P/\%&>4[XIC06RL$MGP;5,VJ,)D5U4< MF5&B*)JONF;@U;8-S9$UR[)OLD6OIGCAIZM&S'O7B&J/7SCR3&5ONSWF7_)* M?C*$: 6L*"YP>,E$\EB4C*50E/E_@NA&1R!=M^Z8^D/D42L??-3B#->HN\;]*DGNZ17^,I=G!X0IDD[C$(VP MU#IYL*3^ZOCG+ US$&8LCAS%Q6)2MAK2>TD2>00D,P?]>)4&I3R>X%._>TW# M\TX/?H^@_?:@U;DPCSJ]\+S_53\_^SQH7T>]]M[EZO$$9^U^6_L<'>V#H3GK MPAB[DZ.]2^QS@,<<=/&HA+.F D9HM2##)I:KV(S))B$J&"3+ECT+ GJ;4M/U M'=/R=1]WV;FV8;Q_W%15Q((597^B<'Z].!#C MTG8KW&6UH=K2[J=C2=.5.MSXH,7/-_4_ 4ON U'CBQ88/QSUF^[_I.Y/5G0_ MH,S1(5"0;:*![ILTD-W L&65:987.!HUB/U7T?VYP$F#0N)6%5\UB*QJ%=U? MV%\YTWP#+#Z_\TWY'Z3\7U*&=A\/FN'[\=&G38^" $/&-Q#X*1"8KH" ;^@Z M40G?7P0@X 8 AI395UCBF&8:J ;?QD' 1/]BN2=Z#!''O M&R@\!B@<9-F(I6_0\'C0<+T"#99"',VS3-G254,V+)?)Q' ]V6(V\8EI>09Q MWZ#A)FC0F6QL^/>#AN+>-=#PLE-5E=A'Y(Y8RN@"+6;G5'"8+')),/]G2AW] MS$8LJZ[HC[\12S/JAO/XS<)H5>=^>Z:>VP0]JIYV\.!<<32#WY/\B&39*RZH MN6&.*>&K:2?3@9=$&[Y(E_**Y(^^1-3'\>:DO77YQBLQRIHH5[_36I3R;)!XN23#W=

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end